Overall, these important recent findings highlight the critical role of NPR-C and its interaction with musclin in reducing the protecting activities of NPs in HF patients, suggesting possible new clinical therapeutic targets for this condition. This evidence concerns the gene NPR3 and hydrops fetalis.